The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre

EuroIntervention 2018;14:e333-e335 published online March 2018 published online e-edition June 2018. DOI: 10.4244/EIJ-D-18-00036

1. Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA; 2. Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA

Oral antiplatelet therapy may require temporary disruption soon after percutaneous coronary intervention (PCI) or acute coronary syndrome, incurring potential thrombotic risks. Glycoprotein IIb/IIIa inhibitors have been used

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Invasive strategy and frailty in very elderly patients with acute coronary syndromes